Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Medivir AB ( (SE:MVIR) ) is now available.
Medivir AB has called its annual general meeting for 7 May 2026 in Stockholm, offering shareholders the option to attend in person or vote in advance via postal and electronic channels. The company outlines detailed procedures for registration, proxy representation, and voting-right registration for nominee-registered shareholders, ensuring broad participation and compliance with Swedish corporate law.
The notice confirms the current share structure, including 538,671,220 ordinary shares and 2,450,163 class C shares held as treasury stock, underscoring Medivir’s capital base ahead of key governance decisions. By formalizing the agenda and reinforcing shareholders’ rights to information, the company signals continued adherence to governance standards that are important for investor confidence and regulatory transparency.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Sweden-based pharmaceutical company focused on the research and development of innovative treatments, primarily in oncology and other specialty disease areas. Listed in Stockholm and headquartered in Huddinge, the company targets global markets through the development of proprietary drug candidates and strategic partnerships.
Average Trading Volume: 10,052,615
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.26B
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.